Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17


Treating Negative Symptoms in Schizophrenia: an Update.

Remington G, Foussias G, Fervaha G, Agid O, Takeuchi H, Lee J, Hahn M.

Curr Treat Options Psychiatry. 2016;3:133-150. Epub 2016 Apr 8. Review.


Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.

Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Gold JM, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman SM, Russ JC, Keefe RS, Osing J, Hubzin L, August S, Walker TM, Buchanan RW.

J Clin Psychopharmacol. 2015 Aug;35(4):374-81. doi: 10.1097/JCP.0000000000000345.


Glutamate and dopamine in schizophrenia: an update for the 21st century.

Howes O, McCutcheon R, Stone J.

J Psychopharmacol. 2015 Feb;29(2):97-115. doi: 10.1177/0269881114563634. Epub 2015 Jan 13. Review.


Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options.

Chue P, Lalonde JK.

Neuropsychiatr Dis Treat. 2014 May 8;10:777-89. doi: 10.2147/NDT.S43404. eCollection 2014. Review.


Clozapine-related EEG changes and seizures: dose and plasma-level relationships.

Varma S, Bishara D, Besag FM, Taylor D.

Ther Adv Psychopharmacol. 2011 Apr;1(2):47-66. doi: 10.1177/2045125311405566.


Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?

Stone JM.

Ther Adv Psychopharmacol. 2011 Feb;1(1):5-18. doi: 10.1177/2045125311400779.


Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.

Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, Correll CU.

Schizophr Bull. 2013 Nov;39(6):1230-41. doi: 10.1093/schbul/sbt070. Epub 2013 May 29. Review.


Beyond dopamine: glutamate as a target for future antipsychotics.

Sendt KV, Giaroli G, Tracy DK.

ISRN Pharmacol. 2012;2012:427267. doi: 10.5402/2012/427267. Epub 2012 Jul 5.


Treatment-resistant Schizophrenia: Evidence-based Strategies.

Englisch S, Zink M.

Mens Sana Monogr. 2012 Jan;10(1):20-32. doi: 10.4103/0973-1229.91588.


Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression?

Dawes SE, Palmer BW, Meeks T, Golshan S, Kasckow J, Mohamed S, Zisook S.

Neuropsychobiology. 2012;65(3):168-72. doi: 10.1159/000331141. Epub 2012 Mar 27.


Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

McCullumsmith RE, Hammond J, Funk A, Meador-Woodruff JH.

Curr Pharm Biotechnol. 2012 Jun;13(8):1535-42. Review.


Pharmacotherapy for treatment-resistant schizophrenia.

McIlwain ME, Harrison J, Wheeler AJ, Russell BR.

Neuropsychiatr Dis Treat. 2011;7:135-49. doi: 10.2147/NDT.S12769. Epub 2011 Mar 17.


Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.

Sommer IE, Begemann MJ, Temmerman A, Leucht S.

Schizophr Bull. 2012 Sep;38(5):1003-11. doi: 10.1093/schbul/sbr004. Epub 2011 Mar 21. Review.


Pharmacologic treatment of schizophrenia.

Kane JM, Correll CU.

Dialogues Clin Neurosci. 2010;12(3):345-57. Review.


A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Honer WG, Procyshyn RM, Chen EY, MacEwan GW, Barr AM.

J Psychiatry Neurosci. 2009 Nov;34(6):433-42. Review.

Supplemental Content

Support Center